These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 21544015

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [Abstract] [Full Text] [Related]

  • 3. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [Abstract] [Full Text] [Related]

  • 4. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A, Rosso R, Loregian A, Pagni S, Sormani MP, Cenderello G, Palù G, Viscoli C.
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [Abstract] [Full Text] [Related]

  • 5. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.
    AIDS; 2007 Nov 30; 21(18):2409-15. PubMed ID: 18025877
    [Abstract] [Full Text] [Related]

  • 6. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E.
    Ther Drug Monit; 2010 Dec 30; 32(6):782-6. PubMed ID: 20926993
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S, De Luca A, Villani P, Bacarelli A, Ragazzoni E, Regazzi M, Cauda R, Navarra P.
    HIV Med; 2008 Apr 30; 9(4):239-45. PubMed ID: 18366448
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.
    J Antimicrob Chemother; 2008 Sep 30; 62(3):579-82. PubMed ID: 18477709
    [Abstract] [Full Text] [Related]

  • 11. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.
    Antivir Ther; 2006 Sep 30; 11(1):53-62. PubMed ID: 16518960
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.
    AIDS; 2006 May 12; 20(8):1131-9. PubMed ID: 16691064
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.
    Gianotti N, Soria A, Lazzarin A.
    New Microbiol; 2007 Apr 12; 30(2):79-88. PubMed ID: 17619250
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
    Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF.
    Antivir Ther; 2010 Apr 12; 15(7):993-1002. PubMed ID: 21041914
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.